Prevention of vertical transmission of HIV-1 in resource-limited settings

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 10, 2010, Pages 1163-1175

  Coutsoudis, Anna ^a   Kwaan, Leith ^a   Thomson, Mairi ^b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

antiretroviral therapy; breastfeeding interventions; drug safety; HIV; PMTCT; post exposure prophylaxis; resistance; resource limited setting; vertical transmission

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PLACEBO; RITONAVIR PLUS SAQUINAVIR; SELENIUM; TENOFOVIR; VITAMIN D; ZIDOVUDINE;

ANEMIA; ANTEPARTUM CARE; BREAST FEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMININE HYGIENE PRODUCT; HEALTH CARE POLICY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; INTRAPARTUM CARE; INTRAUTERINE GROWTH RETARDATION; LIVER TOXICITY; LOW BIRTH WEIGHT; MATERNAL WELFARE; MONOTHERAPY; NONHUMAN; NUTRITIONAL STATUS; OBSTETRIC CARE; PERSONAL HYGIENE; PREGNANCY; PREMATURE LABOR; PUERPERIUM; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; VIRUS LOAD; VIRUS TRANSMISSION; VITAMIN SUPPLEMENTATION; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BREAST FEEDING; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 77958193853     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.94     Document Type: Review

References (116)

1. Bertolli J, St Louis ME, Simonds RJ et al. Estimating the timing of mother-to-child transmission of human immunodefciency virus in a breast-feeding population in Kinshasa, Zaire. J. Infect. Dis. 174, 722-726 (1996).
2. Mock PA, Shaffer N, Bhadrakom C et al. Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand. AIDS 13, 407-414 (1999).
3. Charurat M, Datong P, Matawal B, Ajene A, Blattner W, Abimiku A. Timing and determinants of mother-to-child transmission of HIV in Nigeria. Int. J. Gynecol. Obstet. 106(1), 8-13 (2009).
4. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C et al. Lamividine-zidovudine combination for prevention of maternal-infant transmission of HIV. JAMA 285(16), 2083-2093 (2001).
5. Cooper ER, Charurat M, Mofenson L et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J. Acquir. Immune Defc. Syndr. 29(5), 484-494 (2002).
6. Dorenbaum A, Cunningham CK, Gelber RD et al. Two-dose intra-partum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 288(2), 189-198 (2002).
7. Haberl A, Linde R, Reitter A et al. Safety and effcacy of tenofovir in pregnant women. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008 (Abstract 627a).
8. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 22, 973-981 (2008).
9. von Linstow ML, Rosenfeldt V, Lebech AM et al. Prevention of mother-tochild transmission of HIV in Denmark, 1994-2008. HIV Med. 11(7), 448-456 (2010).
10. Islam S, Oon V, Thomas P. Outcome of pregnancy in HIV-positive women planned for vaginal delivery under effective antiretroviral therapy. J. Obstet. Gynaecol. 30(1), 38-40 (2010).
11. Gumbo FZ, Duri K, Kandawasvika GQ et al. Risk factors of HIV vertical transmission in a cohort of women under a PMTCT program at three peri-urban clinics in a resource-poor setting. J. Perinatol. DOI: 10.1038/jp. 2010.31 (2010) (Epub ahead of print).
12. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodefciency virus type 1: a meta-analysis of 15 prospective cohort studies. N. Engl. J. Med. 340, 977-987 (1999).
13. Zhou Z, Meyers K, Li X et al. Prevention of mother-to-child transmission of HIV-1 using highly active antiretroviral therapy in rural Yunnan, China. J. Acquir. Immune Defc. Syndr. 53 (Suppl. 1), S15-S22 (2010).
14. Connor EM, Sperling RS, Gelber R et al.; The Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodefciency virus type 1 with zidovudine treatment. N. Engl. J. Med. 331(18), 1173-1180 (1994).
15. Dabis F, Msellati P, Meda N et al. 6-Month effcacy, tolerance and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 353(9155), 786-792 (1999).
16. Wiktor SZ, Ekpini E, Karon JM et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 353(9155), 781-785 (1999).
17. Lallemant M, Jourdain G, Le Coeur S et al. A trial of short zidovudine regimens to prevent mother-to-child transmission of human immunodefciency virus type 1. N. Engl. J. Med. 343, 982-991 (2000).
18. Guay LA, Musoke P, Fleming T et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354(9181), 795-802 (1999).
19. Moodley D, Moodley J, Coovadia H et al. A multicentre randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodefciency virus type 1. J. Infect. Dis. 187, 725-735 (2003).
20. The PETRA Study team. Effcacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa and Uganda (PETRA Study): a randomised, double-blind placebo-controlled trial. Lancet 359, 1178-1186 (2002).
21. McIntyre JA, Martinson N, Gray GE et al. Addition of short course combivir (CBV) to single dose viramune (sdNVP) for the prevention of mother to child transmission (pMTCT) of HIV-1 can Significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus. Presented at: 3rd IAS Conference on HIV Pathogenesis and Treatment and Prevention. Rio de Janiero, Brazil, 24-27 July 2005.
22. Arrivé E, Chaix ML, Nerrienet E et al. The TEmAA ANRS 12109 Phase II trial, Step 1: tolerance and viral resistance after single-dose nevirapine and short-course of tenofovir disoproxil fumarate and emtricitabine to prevent mother-to-child transmission of HIV-1. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008 (Abstract 45B).
23. Chi BH, Ellis GM, Chintu N et al. Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention. AIDS Res. Hum. Retroviruses 25(11), 1099-1106 (2009).
24. Fawzi W, Msamanga G, Spielgelman D et al. Randomised trial of effects of vitamin supplements on pregnancy outcomes and T cell counts in HIV-1-infected women in Tanzania. Lancet 351(9114), 1477-1482 (1998).
25. Kawai K, Kupka R, Mugusi F et al. A randomized trial to determine the optimal dosage of multivitamin supplements to reduce adverse pregnancy outcomes among HIV-infected women in Tanzania. Am. J. Clin. Nutr. 91(2), 391-397 (2010).
26. Fawzi W W, Msamanga G, Hunter D et al. Randomized trial of vitamin supplements in relation to vertical transmission of HIV-1 in Tanzania. J. Acquir. Immune Defc. Syndr. 23(3), 246-254 (2000).
27. Kongnyuy EJ, Wiysonge CS, Shey MS. A systematic review of randomized controlled trials of prenatal and postnatal vitamin A supplementation of HIV-infected women. Int. J. Gynaecol. Obstet. 104(1), 5-8 (2009).
28. Kawai K, Msamanga G, Manji K et al. Sex differences in the effects of maternal vitamin supplements on mortality and morbidity among children born to HIV-infected women in Tanzania. Br. J. Nutr. 103(12), 1784-1791 (2010).
29. Mehta S, Giovannucci E, Mugusi FM et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One 5(1), e8770 (2010).
30. Mehta S, Hunter DJ, Mugusi FM et al. Perinatal outcomes, including mother-tochild transmission of HIV, and child mortality and their association with maternal vitamin D status in Tanzania. J. Infect. Dis. 200(7), 1022-1030 (2009).
31. Villamor E, Aboud S, Koulinska IN et al. Zinc supplementation to HIV-1-infected pregnant women: effects on maternal anthropometry, viral load, and early mother-to-child transmission. Eur. J. Clin. Nutr. 60(7), 862-869 (2006).
32. Fawzi W, Villamor E, Msamanga GI et al. Trial of zinc supplements in relation to pregnancy outcomes, hematologic indicators, and T cell counts among HIV-1-infected women in Tanzania. Am. J. Clin. Nutr. 81(1), 161-167 (2005).
33. Kupka R, Garland M, Msamanga G, Spiegelman D, Hunter D, Fawzi W. Selenium status, pregnancy outcomes, and mother-to-child transmission of HIV-1. J. Acquir. Immune Defc. Syndr. 39(2), 203-210 (2005). (Pubitemid 40741120)
34. Kupka R, Mugusi F, Aboud S et al. Randomized, double-blind, placebocontrolled trial of selenium supplements among HIV-infected pregnant women in Tanzania: effects on maternal and child outcomes. Am. J. Clin. Nutr. 87(6), 1802-1808 (2008).
35. Read JS, Newell MK. Effcacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst. Rev. 4, CD005479 (2005).
36. Boer K, England K, Godfried MH, Thorne C; the European Collaborative Study. Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe. HIV Med. 11(6), 368-378 (2010).
37. Biggar RJ, Goedert JJ, Miotti PG et al. Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet 347, 1647-1650 (1996).
38. Msellati P, Meda N, Leroy V et al. Safety and acceptability of vaginal disinfection with benzalkonium chloride in HIV infected pregnant women in west Africa: ANRS 049b Phase II randomized, double blinded placebo controlled trial. DITRAME Study Group. Sex. Transm. Infect. 75, 420-425 (1999).
39. Mandelbrot L, Msellati P, Meda N et al. 15 month follow up of African children following vaginal cleansing with benzalkonium chloride of their HIV infected mothers during late pregnancy and delivery. Sex. Transm. Infect. 78, 267-270 (2002).
40. Jones G, Steketee RW, Black RE, Bhutta ZA, Morris SS; Bellagio Child Survival Study Group. How many child deaths can we prevent this year? Lancet 362, 65-71 (2003).
41. Arifeen S, Black RE, Antelman G, Baqui A, Caulfeld L, Becker S. Exclusive breastfeeding reduces acute respiratory infection and diarrhea deaths among infants in Dhaka slums. Pediatrics 108, E67 (2001).
42. Bhandari N, Bahl R, Mazumdar S et al. Effect of community-based promotion of exclusive breastfeeding on diarrhoeal illness and growth: a cluster randomised controlled trial. Lancet 361, 1418-1423 (2003).
43. Murray CJ, Lopez AD. The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Harvard School of Public Health, Cambridge, MA, USA. Global Burden of Disease and Injury Series, Volume I (1996).
44. Short RV, Lewis PR, Renfree MB, Shaw G. Contraceptive effects of extended lactational amenorrhoea: beyond the Bellagio Consensus. Lancet 337, 715-717 (1991).
45. Stein Z, Kuhn L. Breast feeding: a time to craft new policies. J. Public Health Policy 30, 300-310 (2009).
46. Nelson AM. A metasynthesis of qualitative breastfeeding studies. J. Midwifery Womens Health 51(2), e13-e20 (2006).
47. Creek T. Role of infant feeding and HIV in a severe outbreak of diarrhoea and malnutrition among young children-Botswana, 2006. Presented at: President's Emergency Plan for AIDS Relief Emergency Meeting/2006 HIV/AIDS Implementers' Meeting. Durban, South Africa, 12-15 June 2006.
48. Kuhn L, Reitz C, Abrams EJ. Breastfeeding and AIDS in the developing world. Curr. Opin. Pediatr. 21, 83-93 (2009).
49. Lehman DA, Chung MH, Mabuka JM et al. Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. J. Acquir. Immune Defc. Syndr. 51(5), 522-529 (2009).
50. Palombi L, Marazzi MC, Voetberg A, Magid NA; the DREAM Program Prevention of Mother-to-Child Transmission team. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS 21 (Suppl. 4), S65-S71 (2007).
51. Leroy V, Ekouevi DK, Becquet R et al. 18-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-to-child transmission. PLoS One 3(2), e1645 (2008).
52. Hoffman RM, Black V, Technau K et al. Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa. J. Acquir. Immune Defc. Syndr. 54(1), 35-41 (2010).
53. Shapiro R, Hughes M, Ogwu A et al. A randomized trial comparing highly active antiretroviral therapy regimens for virologic effcacy and the prevention of mother-tochild transmission among breast-feeding women in Botswana (The Mma Bana Study). Presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Cape Town, South Africa, 19-22 July 2009 (Abstract WeLBB101). • This study showed transmission rates of 2% and less in mothers given highly active antiretroviral therapy (HAART) during pregnancy and throughout breastfeeding, with no difference seen between different HAART regimens used.
54. Ekouevi DK, Coffe PA, Becquet R et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire. AIDS 22, 1815-1820 (2008).
55. Tonwe-Gold B, Ekouevi DK, Viho I et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med. 4(8), e257 (2007).
56. Thomas T, Masaba R, Ndivo R et al. Prevention of mother-to-child transmission of HIV-1 among breastfeeding mothers using HAART: the Kisumu Breastfeeding Study, Kisumu, Kenya, 2003-2007 Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008 (Abstract 45aLB).
57. Kilewo C, Karlsson K, Ngarina M et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J. Acquir. Immune Defc. Syndr. 52(3), 406-416 (2009).
58. Peltier CA, Ndayisaba GF, Lepage P et al. Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in Rwanda. AIDS 23(18), 2415-2423 (2009).
59. De Vincenzi I (for Kesho Bora Study Group). Triple-antiretroviral prophylaxis during pregnancy and breast-feeding compared to short-ARV prophylaxis to prevent mother-to-child transmission of HIV-1: the Kesho Bora randomized controlled clinical trial in fve sites in Burkina Faso, Kenya and South Africa. Presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Cape Town, South Africa, 19-22 July 2009 (Abstract LBPeC01).
60. Marazzi MC, Nielsen-Saines K, Buonomo E et al. Increased infant human immunodefciency virus-type one free survival at one year of age in sub-Saharan Africa with maternal use of highly active antiretroviral therapy during breast-feeding. Pediatr. Infect. Dis. J. 28, 483-487 (2009). • The DREAM study: women received HAART during pregnancy and throughout breastfeeding and infants received single-dose nevirapine and 1 week zidovudine, resulting in a cumulative HIV transmission rate of 2.8% at 12 months, and a 50% reduction in infant mortality.
61. Thior I, Lockman S, Smeaton LM et al. Breast-feeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 296, 794-805 (2006).
62. Bedri A, Gudetta B, Isehak A et al. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breast-feeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 372, 300-313 (2008).
63. Kumwenda NI, Hoover DR, Mofenson LM et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N. Engl. J. Med. 359, 119-129 (2008).
64. Kilewo C, Karlsson K, Massawe A et al. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J. Acquir. Immune Defc. Syndr. 48, 315-323 (2008).
65. Chasela C, Hudgens M, Jamieson D et al. Both maternal HAART and daily infant nevirapine are effective in reducing HIV-1 transmission during breastfeeding in a randomized trial in Malawi: 28 week results of the Breast-feeding, Antiretroviral and Nutrition (BAN) Study. Presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Cape Town, South Africa, 19-22 July 2009 (Abstract WeLBC103).
66. Taha TE, Kumwenda J, Cole SR et al. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy. J. Infect. Dis. 200(10), 1490-1497 (2009).
67. Church JD, Omer SB, Guay LA et al. Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J. Infect. Dis. 198, 1075-1082 (2008).
68. Eshleman SH, Guay LA, Mwatha A et al. Characterization of nevirapine resistance mutations in women with subtype A vs D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J. Acquir. Immune Defc. Syndr. 35, 126-130 (2004). (Pubitemid 38133734)
69. + count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355, 2283-2296 (2006).
70. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and those not receiving ART at baseline in the SMART study. J. Infect. Dis. 197, 1133-1144 (2008).
71. Danel C, Moh R, Minga A et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in West Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 367, 1981-1989 (2006).
72. Chaix M, Ekouevi DK, Rouet F et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J. Infect. Dis. 193, 482-487 (2006).
73. Coffe PA, Ekouevi DK, Chaix M et al. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin. Inf. Dis. 46(4), 611-621 (2008).
74. Delaugerre C, Chaix ML, Blanche S et al. Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. Retrovirology 6, 85 (2009).
75. Torres Rivera B, Vallés V, Ríos Olivares E. Prevalence of primary and secondary resistant mutations to antiretroviral drug in a population of Puerto Rican infected with HIV. P. R. Health Sci. J. 21(4), 329-336 (2002).
76. Flys T, Nissley DV, Claasen CW et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J. Infect. Dis. 192, 24-29 (2005).
77. Delaugerre C, Rohban R, Simon A et al. Resistance profle and cross-resistance of HIV-1 among patients failing a nonnucleoside reverse transcriptase inhibitorcontaining regimen. J. Med. Virol. 65(3), 445-448 (2001).
78. Chalermchockcharoenkit A, Culnane M, Chotpitayasunondh T et al. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV. Clin. Infect. Dis. 49(2), 299-305 (2009).
79. Jourdain G, Wagner TA, Ngo-Giang-Huong N et al. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure. Clin. Infect. Dis. 50(10), 1397-1404 (2010).
80. Arrivé E, Newell ML, Ekouevi DK et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int. J. Epidemiol. 36(5), 1009-1021 (2007).
81. Jourdain G, Ngo-Giang-Huong N, Le Coeur S et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N. Engl. J. Med. 351(3), 229-240 (2004).
82. Chi BH, Sinkala M, Stringer EM et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS 21, 957-964 (2007).
83. Lockman S, Shapiro RL, Smeaton LM et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N. Engl. J. Med. 356, 135-147 (2007).
84. Palumbo P, Violari A, Lindsey J et al. Nevirapine (NVP) vs lopinavir-ritonavir (LPV/r)-based antiretroviral therapy (ART) in single dose nevirapine (sdNVP)-exposed HIV-infected infants: preliminary results from the IMPAACT P1060 trial. Presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, 19-22 July 2009 (Abstract LBPEB12).
85. Martinson NA, Ekouevi DK, Dabis F et al. Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa, and Abidjan, Cote d'Ivoire. J. Acquir. Immune Defc. Syndr. 45, 206-209 (2007).
86. Eshleman SH, Mracna M, Guay LA et al. Selecting and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 15, 1951-1957 (2001).
87. Stringer JS, McConnell MS, Kiarie J et al. Effectiveness of non-nucleoside reversetranscriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study. PLoS Med. 7(2), e1000233 (2010).
88. Micek MA, Blanco AJ, Beck IA et al. Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine. Clin. Infect. Dis. 50(10), 1405-1414 (2010).
89. McIntyre JA, Hopley M, Moodley D et al. Effcacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Clin. Trials 6(10), 1-9 (2009).
90. Jamisse L, Balkus J, Hitti J et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J. Acquir. Immune Defc. Syndr. 44, 371-376 (2007).
91. Gingelmaier A, Eberle J, Kost BP et al. Protease inhibitor-based antiretroviral prophylaxis during pregnancy and the development of drug resistance. Clin. Infect. Dis. 50(6), 890-894 (2010).
92. Ginglemaier A, Kurowski M, Kastner R et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 20, 1737-1743 (2006).
93. Burchette S, Best B, Mirochnick M et al. Tenofovir pharmacokinetics during pregnancy, at delivery and postpartum. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25-28 February 2007 (Abstract 738b).
94. Ivanovic J, Nicastri E, Anceschi MM et al. Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women. Curr. HIV Res. 7(6), 620-625 (2009).
95. Bennetto-Hood C, Bryson YJ, Stek A, King JR, Mirochnick M, Acosta EP. Zidovudine, lamivudine, and nelfnavir concentrations in amniotic fuid and maternal serum. HIV Clin. Trials 10(1), 41-47 (2009).
96. McKoy JM, Bennett CL, Scheetz MH et al. Hepatotoxicity associated with long-versus short-course HIV-prophylactic nevirapine use. Drug Safety 32(2), 147-158 (2009).
97. Le Chenadec J, Mayaux M, Guihenneuc-Jouyaux C, Blanche S; Enquete Perinatale Francaise Study Group. Perinatal antiretroviral treatment and haematopoiesis in HIV-uninfected infants. AIDS 17, 2053-2061 (2003).
98. Lahoz R, Noguera A, Rovira N et al. Antiretroviral-related hematologic short-term toxicity in healthy infants: implications of the new neonatal 4-week zidovudine regimen. Pediatr. Infect. Dis. J. 29(4), 376-379 (2010).
99. Tuomala RE, Shapiro DE, Mofenson LM et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N. Engl. J. Med. 346, 1863-1870 (2002).
100. Thorne C, Patel D, Newell M. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 18, 2337-2339 (2004).
101. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-1 infected women in the United Kingdom and Ireland. AIDS 21, 1019-1026 (2007).
102. Briand N, Mandelbrot L, Le Chenadec J et al. No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS 23(10), 1235-1243 (2009).
103. Briand N, Lallemant M, Jourdain G et al. Haematological safety of perinatal zidovudine in pregnant HIV-1-infected women in Thailand: secondary analysis of a randomized trial. PLoS Clin. Trial 2(4), e11 (2007).
104. Williams PL, Marino M, Malee K, Brogly S, Hughes MD, Mofenson LM; PACTG 219C Team. Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants. Pediatrics 125(2), e250-e260 (2010).
105. Foster C, Lyall H, Olmscheid B, Pearce G, Zhang S, Gibb DM. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? HIV Med. 10(7), 397-406 (2009).
106. The Kesho Bora Study Group. HIV free survival at 12 months among children born to HIV-infected women receiving antiretrovirals (ARVs) from 18-36 weeks of pregnancy. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008 (Abstract 638).
107. Baek C, Rutenberg N. Implementing programs for the prevention of mother-tochild HIV transmission in resourceconstrained settings: horizons studies, 1999-2007. Public Health Reports 125(2), 293-304 (2010).
108. Nyandiko WM, Otieno-Nyunya B, Musick B et al. Outcomes of HIV-exposed children in western Kenya: effcacy of prevention of mother to child transmission in a resource-constrained setting. J. Acquir. Immune Defc. Syndr. 54(1), 42-50 (2010).
109. Chen JY, Ogwu AC, Svab P et al. Antiretroviral treatment initiation among HIV-infected pregnant women with low CD4+ cell counts in Gaborone, Botswana. J. Acquir. Immune Defc. Syndr. 54(1), 102-106 (2010).
110. Peltzer K, Mlambo G. Factors determining HIV viral testing of infants in the context of mother-to-child transmission. Acta Paediatr. 99(4), 590-596 (2010).
111. Kasenga F, Byass P, Emmelin M, Hurtig AK. The implications of policy changes on the uptake of a PMTCT programme in rural Malawi: first three years of experience. Glob. Health Action DOI: 10.3402/gha.v2i0.1883 (2009) (Epub ahead of print).
112. Mandala J, Torpey K, Kasonde P et al. Prevention of mother-to-child transmission of HIV in Zambia: implementing effcacious ARV regimens in primary health centers. BMC Public Health 9, 314 (2009).
113. Torpey K, Kabaso M, Kasonde P et al. Increasing the uptake of prevention of mother-to-child transmission of HIV services in a resource-limited setting. BMC Health Serv. Res. 10, 29 (2010).
114. Petruney T, Robinson E, Reynolds H, Wilcher R, Cates W. Contraception is the best kept secret for prevention of motherto-child HIV transmission. Bull. World Health Organ. 86(6), B (2008).
115. Peltzer K, Chao L-W, Dana P. Family planning among HIV positive and negative prevention of mother to child transmission (PMTCT) clients in a resource poor setting in South Africa. AIDS Behav. 13(5), 973-979 (2009).
116. Nuesch R, Ananworanich J, Srasuebkul P et al. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. AIDS 22(1), 152-154 (2008).